Sung H, Ferlay J, Siegel RL et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–249.

PubMed  Google Scholar 

Reeves EP, Ali T, Leonard Pet al. (2008) Helicobacter pylori lipopolysaccharide interacts with TFF1 in a pH-dependent manner. Gastroenterology. 135:2043–2054, 2054 e2041–2042.

Ito N, Tsujimoto H, Ueno H, Xie Q, Shinomiya N. (2020) Helicobacter pylori-Mediated Immunity and Signaling Transduction in Gastric Cancer. J Clin Med. 9.

Shetab Boushehri MA, Lamprecht A. TLR4-Based Immunotherapeutics in Cancer: A Review of the Achievements and Shortcomings. Mol Pharm. 2018;15:4777–4800.

Article  PubMed  Google Scholar 

Yuan X, Zhou Y, Wang W et al. Activation of TLR4 signaling promotes gastric cancer progression by inducing mitochondrial ROS production. Cell Death Dis. 2013;4:e794.

Article  PubMed  PubMed Central  Google Scholar 

Fahraeus R, Olivares-Illana V. MDM2’s social network. Oncogene. 2014;33:4365–4376.

Article  PubMed  Google Scholar 

Jiang X, Yuan J, Dou Y, Zeng D, Xiao S. Lipopolysaccharide Affects the Proliferation and Glucose Metabolism of Cervical Cancer Cells Through the FRA1/MDM2/p53 Pathway. Int J Med Sci. 2021;18:1030–1038.

Article  PubMed  PubMed Central  Google Scholar 

Qi M, Yi X, Yue B, Huang M, Zhou S, Xiong J. S100A6 inhibits MDM2 to suppress breast cancer growth and enhance sensitivity to chemotherapy. Breast Cancer Res. 2023;25:55.

Article  PubMed  PubMed Central  Google Scholar 

Chen Y, Wang DD, Wu YP et al. MDM2 promotes epithelial-mesenchymal transition and metastasis of ovarian cancer SKOV3 cells. Br J Cancer. 2017;117:1192–1201.

Article  PubMed  PubMed Central  Google Scholar 

Meng X, Franklin DA, Dong J, Zhang Y. MDM2-p53 pathway in hepatocellular carcinoma. Cancer Res. 2014;74:7161–7167.

Article  PubMed  PubMed Central  Google Scholar 

Zhao Y, Aguilar A, Bernard D, Wang S. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment. J Med Chem. 2015;58:1038–1052.

Article  PubMed  Google Scholar 

Fang DD, Tang Q, Kong Y et al. MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment. J Immunother Cancer. 2019;7:327.

Article  PubMed  PubMed Central  Google Scholar 

Lin TY, Hsu HY. Ling Zhi-8 reduces lung cancer mobility and metastasis through disruption of focal adhesion and induction of MDM2-mediated Slug degradation. Cancer Lett. 2016;375:340–348.

Article  PubMed  Google Scholar 

Li P, Shi JX, Dai LP et al. Serum anti-MDM2 and anti-c-Myc autoantibodies as biomarkers in the early detection of lung cancer. Oncoimmunology. 2016;5:1138200.

Article  Google Scholar 

Schmidinger B, Petri K, Lettl C et al. Helicobacter pylori binds human Annexins via Lipopolysaccharide to interfere with Toll-like Receptor 4 signaling. PLoS Pathog. 2022;18:1010326.

Article  Google Scholar 

Zhou XY, Fang DL, Liu HHet al. (2022) PMN-MDSCs accumulation induced by CXCL1 promotes CD8T cells exhaustion in gastric cancer. Cancer Letters. 532.

Kim EK, Choi EJ. Compromised MAPK signaling in human diseases: an update Arch Toxicol. 2015;89:867–882.

Google Scholar 

Vassilev LT, Vu BT, Graves B et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004;303:844–848.

Article  PubMed  Google Scholar 

Li R, Zatloukalova P, Muller P et al. The MDM2 ligand Nutlin-3 differentially alters expression of the immune blockade receptors PD-L1 and CD276. Cell Mol Biol Lett. 2020;25:41.

Article  PubMed  PubMed Central  Google Scholar 

Endo S, Yamato K, Hirai S et al. Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells. Cancer Sci. 2011;102:605–613.

Article  PubMed  Google Scholar 

Zou Q, Jin J, Hu H et al. USP15 stabilizes MDM2 to mediate cancer-cell survival and inhibit antitumor T cell responses. Nat Immunol. 2014;15:562–570.

Article  PubMed  PubMed Central  Google Scholar 

Zhou J, Kryczek I, Li S et al. The ubiquitin ligase MDM2 sustains STAT5 stability to control T cell-mediated antitumor immunity. Nat Immunol. 2021;22:460–470.

Article  PubMed  PubMed Central  Google Scholar 

Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol. 2012;30:531–564.

Article  PubMed  PubMed Central  Google Scholar 

Fock KM. Review article: the epidemiology and prevention of gastric cancer. Aliment Pharmacol Ther. 2014;40:250–260.

Article  PubMed  Google Scholar 

Hou H, Sun D, Zhang X. The role of MDM2 amplification and overexpression in therapeutic resistance of malignant tumors. Cancer Cell Int. 2019;19:216.

Article  PubMed  PubMed Central  Google Scholar 

Nakajima N, Ito Y, Yokoyama K et al. The Expression of Murine Double Minute 2 (MDM2) on Helicobacter pylori-Infected Intestinal Metaplasia and Gastric Cancer. J Clin Biochem Nutr. 2009;44:196–202.

Article  PubMed  PubMed Central  Google Scholar 

Yang Z, Shu X, Chen L, Chen J, Xie Y, Lu NH. Expression of p53-MDM2 feedback loop related proteins in different gastric pathologies in relation to Helicobacter pylori infection: implications in gastric carcinogenesis. Clin Res Hepatol Gastroenterol. 2012;36:235–243.

Article  PubMed  Google Scholar 

Barros R, Freund JN, David L. Almeida R. Gastric intestinal metaplasia revisited: function and regulation of CDX2. Trends Mol Med. 2012;18:555–563.

Article  PubMed  Google Scholar 

Kodama M, Fujioka T, Murakami K et al. Eradication of Helicobacter pylori reduced the immunohistochemical detection of p53 and MDM2 in gastric mucosa. J Gastroenterol Hepatol. 2005;20:941–946.

Article  PubMed  Google Scholar 

Sijmons D, Guy AJ, Walduck AK, Ramsland PA. Helicobacter pylori and the Role of Lipopolysaccharide Variation in Innate Immune Evasion. Front Immunol. 2022;13:868225.

Article  PubMed  PubMed Central  Google Scholar 

Sasaran MO, Melit LE, Dobru ED. (2021) MicroRNA Modulation of Host Immune Response and Inflammation Triggered by Helicobacter pylori. Int J Mol Sci. 22.

Ogawa T, Suda Y, Kashihara W et al. Immunobiological activities of chemically defined lipid A from Helicobacter pylori LPS in comparison with Porphyromonas gingivalis lipid A and Escherichia coli-type synthetic lipid A (compound 506). Vaccine. 1997;15:1598–1605.

Article  PubMed  Google Scholar 

Chochi K, Ichikura T, Kinoshita M et al. Helicobacter pylori augments growth of gastric cancers via the lipopolysaccharide-toll-like receptor 4 pathway whereas its lipopolysaccharide attenuates antitumor activities of human mononuclear cells. Clin Cancer Res. 2008;14:2909–2917.

Article  PubMed  Google Scholar 

Silva LM, Correia VG, Moreira ASP et al. Helicobacter pylori lipopolysaccharide structural domains and their recognition by immune proteins revealed with carbohydrate microarrays. Carbohydr Polym. 2021;253:117350.

Article  PubMed  Google Scholar 

Abdullazade S, Behrens HM, Kruger S, Haag J, Rocken C. MDM2 amplification is rare in gastric cancer. Virchows Arch. 2023;483:795–807.

Article  PubMed  PubMed Central  Google Scholar 

Shaulian E, Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol. 2002;4:E131-136.

Article  PubMed  Google Scholar 

Kajanne R, Miettinen P, Mehlem A et al. EGF-R regulates MMP function in fibroblasts through MAPK and AP-1 pathways. J Cell Physiol. 2007;212:489–497.

Article  PubMed  Google Scholar 

Manfredi JJ. The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. Genes Dev. 2010;24:1580–1589.

Article  PubMed  PubMed Central  Google S